

State Bank of India

05 May 2025

RESULT UPDATE

Sector: Banks	Rating: BUY
CMP: Rs 800	Target Price: Rs 940

Stock Info

Sensex/Nifty	80,501 / 24,346
Bloomberg	SBIN IN
Equity shares	8925mn
52-wk High/Low	Rs 912/679
Face value	Rs 1
M-Cap	Rs 7,140bn/ USD 84bn
3-m Avg value	USD 110mn

Financial Snapshot (Rs bn)

Y/E March	FY25	FY26E	FY27E
NII	1,670	1,839	2,038
PPP	1,106	1,187	1,311
PAT	709	758	805
EPS (Rs)	79	85	90
EPS Gr. (%)	16	7	6
BV/Sh (Rs)	463	531	604
Adj. BV/Sh (Rs)	447	514	584

Ratios

NIM (%)	2.8	2.8	2.8
C/I ratio (%)	51.6	52.0	51.5
RoA (%)	1.1	1.1	1.0
RoE (%)	18.6	17.1	15.9
Payout (%)	20.0	20.0	20.0

Valuations

P/E (x)	7.7	7.2	6.8
P/BV (x)	1.3	1.1	1.0
P/Adj. BV (x)	1.4	1.2	1.0
Div. Yield (%)	2.0	2.1	2.3

Shareholding pattern (%)

	Sep'24	Dec'24	Mar'24
Promoter	58	57	57
-Pledged			
FII	11	10	10
DII	24	25	25
Others	8	7	8

Stock Performance (1-year)



Pashmi Chheda

pashmichheda@systematixgroup.in
+91 22 6704 8063

Profitability supported by treasury gains and one-offs. Growth outlook soft.

SBI reported 4QFY25 PAT of Rs 186bn (+10% qoq, -10% yoy) supported by higher treasury gains on gains from revaluation of government guaranteed SRs. NII growth of 3% qoq, 3% yoy remained weak due to weak loan growth. FY26 growth outlook of 12-13% was also soft. However, asset quality continues to remain stable.

The key result highlights were: (1) Gross advances growth of 3.8% qoq 12% yoy was lower than guidance of 14-16% due to unanticipated corporate prepayments from central PSUs as a result of deleveraging via equity funding. (2) Deposit growth was 3% qoq, 9.5% yoy, in-line with FY25 guidance of 10% led by seasonally strong CASA growth of 5% qoq, 6% yoy. (3) FY25 global NIM of 3.09% was higher than guidance of >3%. (4) Other income increased 2x qoq aided by higher treasury gains on falling yields and seasonally strong fee income, Rs 33bn benefit from revaluation of government guaranteed SRs and higher miscellaneous income on higher dividend from subsidiaries. (5) Opex/assets increased to 1.379% (+3bps qoq) due to front loaded provisioning under PLI (performance-linked incentives) scheme. (6) 4Q had provision reversal of Rs 5bn on government guaranteed SRs excluding which credit costs would have been 44bps. (7) FY25 RoA of 1.1% vs 1.04% in FY24.

We reduce our FY26 growth estimates on the back of soft loan growth guidance and impact on profitability to be offset by higher treasury gains on falling yields. We retain our estimates Mar'26 TP of Rs 940 valuing the standalone bank at 1.3x Mar'27 adj BVPS and assigning a value of Rs 190 per share to the subsidiaries. Retain BUY.

FY25 Loan growth weaker than expected and FY26 outlook remains soft: Gross advances growth of 3.8% qoq 12% yoy was lower than guidance of 14-16% due to unanticipated corporate prepayments from central PSUs as a result of deleveraging via equity funding. Credit growth was led by Corporate credit growth of 5.5% qoq, 9% yoy and Retail credit growth of 4.1% qoq, 11% yoy. However, SME credit growth was weak sequentially at 1.9% qoq, 17% yoy. This is as opposed to peer banks witnessing strong SME growth sequentially. Unsecured xpress credit growth remained weak at 1.5% qoq, flat yoy due to tightening of credit filters and revamping of digital infra. **However, bank guided for double digit growth in FY26 in xpress credit. FY26 credit growth guidance was soft at 12-13% yoy.**

FY26 margin to be around 3% despite impact from policy rate cut: Deposit growth was 3% qoq, 9.5% yoy, in-line with FY25 guidance of 10% led by seasonally strong CASA growth of 5% qoq, 6% yoy. Domestic CASA ratio increased to 40% (+77bp qoq). Domestic C-D ratio increased to 69.7% (+77bps qoq). 4QFY25 NIM was largely stable at 3% (+1bp qoq). FY25 global NIM of 3.09% was higher than guidance of >3%. FY25 Domestic NIM declined 3.22% (-3bp yoy) led by domestic C-D ratio increase of +136bp yoy as domestic spreads (YoA-CoD) remained largely stable despite some impact of the 25bps repo rate cut in Feb'25. Going forward, bank expects NIMs to be under pressure due to anticipated repo rate cuts of 50-75bps. However, **bank will protect FY26 NIM around 3% via TD rate cuts and increase in unsecured xpress credit and renewed focus on CA balances.**

Investors are advised to refer disclosures made at the end of the research report.

PPOP growth supported mainly due to higher other income: Other income increased 2x qoq aided by higher treasury gains on falling yields and seasonally strong fee income, Rs 33bn benefit from revaluation of government guaranteed SRs and higher miscellaneous income on higher dividend from subsidiaries. Opex/assets increased to 1.379% (+3bps qoq) due to front loaded provisioning under PLI (performance-linked incentives) scheme. However, FY25 employee costs of Rs 643bn (-18% yoy) were lower than guidance of Rs 650-700bn (2-10% decline yoy). Staff cost growth expected to be moderate (~5-6% yoy), with no significant wage hikes anticipated. Pension provisions may rise if bond yields decline further. **However, FY26 CIR to be around ~51% (FY25: 51.6%).** 4QFY25 PPOP growth of 32.8% qoq, 9% yoy was led by strong loan growth and higher other income.

Asset quality improved qoq with credit costs remaining with guidance: GNPA declined by -25bp qoq to 1.82% mainly led by higher write-offs likely from the SMA book. Gross slippage ratio remained stable at 43bp. Credit costs increased to 39bp vs 23bp in 3Q which was supported by std asset provision reversal on restructured account in 3Q. That said, 4Q also had provision reversal of Rs 5bn on government guaranteed SRs excluding which credit costs would have been 44bps. However, FY25 credit cost of 38bps (ex provision reversal of Rs 5bn) was in-line with guidance of <50bps. Xpress Credit GNPA improved slightly to 1.07% from 1.11%

Valuation & recommendation: We reduce our FY26 growth estimates on the back of soft loan growth guidance and impact on profitability to be offset by higher treasury gains on falling yields. We retain our estimates Mar'26 TP of Rs 940 valuing the standalone bank at 1.3x Mar'27 adj BVPS and assigning a value of Rs 190 per share to the subsidiaries. Retain BUY.

Exhibit 1: Quarterly performance


(INR, Bn)	4QFY25	4QFY24	YoY (%)	3QFY25	QoQ (%)
Interest income	1,197	1,110	8%	1,174	1.9%
Interest expenses	769	694	11%	760	1.2%
NII	428	417	3%	414	3.2%
Other income	242	174	39%	110	119.3%
Operating income	670	590	13%	525	27.6%
Operating expenses	357	303	18%	289	23.4%
- Staff expenses	180	163	10%	161	12.0%
PPOP	313	287	9%	236	32.8%
Provisions	64	16	300%	9	607.1%
PBT	248	271	-8%	226	9.7%
Taxes	62	64	-4%	57	7.9%
PAT	186	207	-10%	169	10.4%
<hr/>					
Key Ratios (%)	4QFY25	4QFY24	YoY (bps)	3QFY25	QoQ (bps)
Domestic CASA Ratio	40.0%	41.1%	-114 bp	39.2%	77 bp
CD Ratio	77.4%	75.3%	201 bp	76.6%	78 bp
NIM (reported)	3.0%	3.3%	-28 bp	3.0%	-1 bp
Cost to Income	53.3%	51.3%	200 bp	55.1%	-184 bp
Credit costs	0.44%	0.36%	7 bp	0.23%	20 bp
GNPA (%)	1.82%	2.2%	-42 bp	2.1%	-25 bp
NNPA (%)	0.47%	0.6%	-10 bp	0.5%	-6 bp
PCR (%)	74.4%	75.0%	-60 bp	74.7%	-24 bp
CAR	14.3%	14.3%	-3 bp	13.0%	122 bp
Tier-I	12.1%	11.9%	18 bp	10.9%	126 bp

Source: Company, Systematix Institutional Research


Exhibit 2: DuPont analysis

Du Pont (% of average assets)	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Net interest income	2.7%	2.7%	2.7%	2.7%	2.6%	2.6%
Other income	0.8%	1.1%	0.7%	1.0%	0.7%	1.5%
Total income	3.5%	3.9%	3.4%	3.6%	3.2%	4.0%
Operating expenses	2.6%	2.0%	1.7%	1.76%	1.79%	2.15%
Employee expenses	1.8%	1.1%	1.0%	0.9%	1.0%	1.1%
PPOP	0.9%	1.9%	1.7%	1.9%	1.5%	1.9%
Provisions	0.0%	0.1%	0.2%	0.3%	0.1%	0.4%
PBT	0.9%	1.8%	1.5%	1.6%	1.4%	1.5%
PAT (RoAA)	0.6%	1.4%	1.1%	1.2%	1.0%	1.1%
Leverage	15.44	15.53	15.24	14.67	14.51	14.51
ROE	9.6%	21.2%	16.8%	17.2%	15.1%	16.3%


Source: Company, Systematix Institutional Research

Exhibit 3: FY25 Credit growth muted on yoy basis


Source: Company, Systematix Institutional Research

Exhibit 4: mainly led by corporate and retail credit


Source: Company, Systematix Institutional Research

Exhibit 5: seasonally strong CA flows


Source: Company, Systematix Institutional Research

Exhibit 6: FY25 margin greater than 3% guidance


Source: Company, Systematix Institutional Research

Exhibit 7: Other income benefit on lower treasury gains


Source: Company, Systematix Institutional Research

Exhibit 8: Higher employee costs due to one-offs


Source: Company, Systematix Institutional Research

Exhibit 9: FY25 credit costs of 38bps, lower than guidance


Source: Company, Systematix Institutional Research

Exhibit 10: Asset quality improved qoq


Source: Company, Systematix Institutional Research

Exhibit 11: CAR at 14.25%


Source: Company, Systematix Institutional Research

Exhibit 12: Bank delivered RoA of 1.1%

Source: Company, Systematix Institutional Research

Exhibit 13: 1-year forward P/ABV (x) trajectory

Source: Company, Systematix Institutional Research

Exhibit 14: SBIN trades around long-term average forward multiple

Source: Company, Systematix Institutional Research

FINANCIALS

Profit & Loss Statement

YE: Mar (Rs bn)	FY23	FY24	FY25	FY26E	FY27E
Interest Income	3,321	4,151	4,625	5,113	5,712
Interest Expenses	1,873	2,553	2,955	3,274	3,674
Net Interest Income	1,448	1,599	1,670	1,839	2,038
Change (%)	20	10	4	10	11
Commission, Ex. & Br. Inc.	262	281	309	337	388
Add: Other income	104	236	307	297	277
Net Income	1,815	2,116	2,286	2,472	2,703
Change (%)	13	17	8	8	9
Operating Expenses	977	1,249	1,181	1,286	1,392
Operating Profit	837	867	1,106	1,187	1,311
Change (%)	23	4	28	7	10
Provisions	165	49	153	172	233
PBT	672	818	952	1,014	1,078
Tax	170	207	244	257	273
Tax Rate (%)	25	25	26	25	25
PAT	502	611	709	758	805
Change (%)	59	22	16	7	6
Proposed Dividend	100	122	142	152	161

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs bn)	FY23	FY24	FY25	FY26E	FY27E
Capital	8.9	8.9	8.9	8.9	8.9
Reserves & Surplus	3,267	3,764	4,403	5,009	5,653
Net Worth	3,276	3,772	4,412	5,018	5,662
Change (%)	17	15	17	14	13
Deposits	44,238	49,161	53,822	60,108	67,415
Change (%)	9	11	9	12	12
CASA Ratio (%)	43	40	38	37	36
Borrowings	4,931	5,976	5,636	6,300	6,872
Other Liabilities	2,725	2,888	2,891	3,180	3,498
Total Liabilities	55,170	61,797	66,761	74,606	83,448
Change (%)	11	12	8	12	12
Investments	15,704	16,713	16,906	18,123	19,428
Cash & Bank balance	3,079	3,108	3,402	3,992	4,467
Loans	31,993	37,040	41,633	46,899	53,435
Change (%)	17	16	12	13	14
Fixed Assets	424	426	441	478	522
Other Assets	3,971	4,510	4,378	5,115	5,596
Total Assets	55,170	61,797	66,761	74,606	83,448

Source: Company, Systematix Institutional Research

Dupont

YE: Mar (%)	FY23	FY24	FY25	FY26E	FY27E
Interest Income	6.3	7.1	7.2	7.2	7.2
Interest Expended	3.6	4.4	4.6	4.6	4.6
Net Interest Income	2.8	2.7	2.6	2.6	2.6
Commission, Exc. & Brokerage	0.5	0.5	0.5	0.5	0.5
Other Fee Income	0.1	0.3	0.2	0.2	0.2
Net Operating Income	3.4	3.5	3.3	3.3	3.3
Profit on sale of investment	0.1	0.1	0.2	0.2	0.1
Net Income	3.5	3.6	3.6	3.5	3.4
Operating Expenses	1.9	2.1	1.8	1.8	1.8
Operating Income	1.6	1.5	1.7	1.7	1.7
Provisions	0.3	0.1	0.2	0.2	0.3
PBT	1.3	1.4	1.5	1.4	1.4
Tax	0.32	0.35	0.38	0.36	0.35
PAT	1.0	1.0	1.1	1.1	1.0
Leverage	19	18	17	16	16
RoE	18.1	18.8	18.6	17.1	15.9

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY23	FY24	FY25	FY26E	FY27E
Spreads Analysis (%)					
Yield on Advances	7.5	8.4	8.4	8.5	8.6
Yield on Earning Assets	6.9	7.7	7.8	7.8	7.8
Cost of Deposits	3.8	4.7	5.0	5.1	5.1
Cost of Funds	4.0	4.9	5.2	5.2	5.2
NIM	3.0	3.0	2.8	2.8	2.8
Profitability Ratios (%)					
Cost/Income	53.9	59.0	51.6	52.0	51.5
PPOP / Avg. assets	1.6	1.5	1.7	1.7	1.7
RoE	18.1	18.8	18.6	17.1	15.9
RoA	1.0	1.0	1.1	1.1	1.0
Asset Quality (%)					
GNPA (Rs bn)	909	843	769	830	931
NNPA (Rs bn)	215	211	197	213	237
GNPA	2.8	2.2	1.8	1.7	1.7
NNPA	0.7	0.6	0.5	0.5	0.4
PCR					
Capitalisation (%)					
CAR	14.7	14.3	15.1	15.2	14.9
Tier I	12.1	11.9	13.2	13.5	13.4
Tier II	2.6	2.4	1.9	1.8	1.6
Average Leverage on Assets (x)	18.9	18.0	16.8	15.9	15.6
Valuations					
Book Value (Rs)	332	388	463	531	604
Adj. Book Value (Rs)	318	374	447	514	584
Price-BV (x)	1.8	1.6	1.3	1.1	1.0
Price-Adj. BV (x)	1.9	1.6	1.4	1.2	1.0
EPS (Rs)	56	68	79	85	90
EPS Growth (%)	59	22	16	7	6
Price-Earnings (x)	10.8	8.9	7.7	7.2	6.8
Dividend (Rs)	11.3	13.7	15.9	17.0	18.0
Dividend Yield (%)	1.4	1.7	2.0	2.1	2.3

Source: Company, Systematix Institutional Research

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Pashmi Chheda**, hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

II. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917